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VEGF signaling through VEGFR2 is a central regulator of the angiogenic response.
Inhibition of VEGF signaling by the stress-induced matricellular protein TSP1 plays a role
in modulating the angiogenic response to VEGF in both health and disease. TSP1 binding
to CD47 inhibits VEGFR2 activation. The full implications of this inhibitory interaction are
unknown. We developed a detailed rule-based computational model to inquire if TSP1-
CD47 signaling through VEGF had downstream effects upon ERK1/2 and calcium. Our
Simulations suggest that enhanced degradation of VEGFR2 initiated by the binding of
TSP1 to CD47 is sufficient to explain the inhibition of VEGFR2 phosphorylation, calcium
elevation, and ERK1/2 activation downstream of VEGF. A complementary mechanism
involving the recruitment of phosphatases to the VEGFR2 complex with consequent
increase in the rate of receptor dephosphorylation may augment the inhibition of the
VEGF signal. The model was then utilized to simulate the effect of inhibiting external TSP1
or the depletion of CD47 as potential therapeutic strategies in restoring VEGF signaling.
Results suggest that depleting CD47 is a more efficient strategy in inhibiting the effects of
TSP1/CD47 on VEGF signaling. Our results highlight the utility of in silico investigations in
elucidating and clarifying molecular mechanisms at the intersection of TSP1 and VEGF
biology and in differentiating between competing pro-angiogenic therapeutic strategies
relevant to peripheral arterial disease (PAD) and wound healing.
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INTRODUCTION
VEGF is crucial in normal angiogenesis during embryonic vascular development (Breier et al.,
1992; Breier, 2000), wound healing (Bao et al., 2009), and the control of adult vascular permeability
and homeostasis (Ku et al., 1993; Lee et al., 2007; Curwen et al., 2008; Lazarus and Keshet, 2011).
Under pathological angiogenesis such as cancer, VEGF is also crucial in the development of tumor
vasculature and subsequent metastasis (Saharinen et al., 2011). In ocular diseases such as age-
related macular degeneration and macular edema, elevated VEGF results in abnormal increase in
vascular permeability and aberrant vascular growth in the eye (Miller et al., 2013). In peripheral
arterial disease (PAD), the blood flow to the lower extremities is compromised as a result of
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atherosclerotic occlusion leading to vascular loss. This may partly
be attributable to the inhibition of pro-angiogenic signaling
and endothelial cell resistance to VEGF (Annex, 2013). An
important arm of VEGF signaling is initiated by its binding
on endothelial cells to its cognate receptor, vascular endothelial
growth factor receptor type 2 (VEGFR2), and the co-receptor
neutopilin-1 (NRP1). The signaling cascades downstream of
VEGFR2 support endothelial cell survival, proliferation, and
motility while suppressing inflammation. VEGF-VEGFR2-NRP1
interaction also leads to the activation of endothelial nitric oxide
synthase and the generation of the biogas nitric oxide (NO) with
subsequent increase in vascular permeability and vasodilation.
Clinically, development of antibodies targeting VEGF as well
as kinase inhibitors targeting VEGFR2 have been effective in
controlling pathological angiogenesis in diseases characterized by
abnormal angiogenesis such as age related macular degeneration,
diabetes induced macular edema, and cancer (Rosenfeld et al.,
2006; Tah et al., 2015; Ferrara and Adamis, 2016).
Physiological angiogenesis is regulated by endogenous
inhibitors with diverse set of mechanisms of inhibition
(Folkman, 2004). These largely secreted inhibitors function in
the extracellular space by binding and sequestering VEGF or
by binding to endothelial cell receptors that initiate signaling
cascades that inhibit calcium elevation, NO release, proliferation,
and motility. Thrombospondin-1 (TSP1) is a large multi-domain
trimeric secreted glycoprotein and among the first identified
potent endogenous inhibitors of angiogenesis (Bagavandoss and
Wilks, 1990; Good et al., 1990; Taraboletti et al., 1990). The ability
of TSP1 to alter cell responses is mediated through interactions
with growth factors, cell membrane receptors, and matrix
(Isenberg et al., 2009). At nanomolar concentrations, TSP1 can
inhibit VEGF signaling by direct binding and sequestering of
VEGF (Gupta et al., 1999) or by inducing VEGF/TSP1 complex
internalization (Greenaway et al., 2007). At these concentrations,
TSP1 can also inhibit the activation of eNOS by AKT via its
interaction with the cell surface receptor CD36 (Isenberg et al.,
2007). However, at physiological TSP1 concentrations (100–
200 pM) endothelial CD47 is a dominant receptor for TSP1.
CD47- and TSP1-null animals show enhanced angiogenesis
and would healing (Isenberg et al., 2008; Soto-Pantoja et al.,
2014). TSP1 interaction with CD47 not only inhibits signaling
downstream of NO by inhibiting soluble guanylate cyclase
(sGC) and cGMP dependent protein kinase (Isenberg et al.,
2006), but it also achieves inhibition of VEGFR2 activation
at physiological concentrations (Kaur et al., 2010). Recent
evidence suggests that CD47 is pre-associated with VEGFR2
under basal conditions and that TSP1 binding leads to the
dissociation of the receptor complex in endothelial cells (Kaur
et al., 2010). However, the dissociation between CD47 and
VEGFR2 in response to TSP1 is not observed in T cells (Kaur
et al., 2014). Although the exact mechanism of action of TSP1
is not yet clear, the CD47-VEGFR2 dissociation is proposed
to be the initiating mechanism for the inhibition of VEGFR2
phosphorylation. There is also limited evidence suggesting
that VEGFR2 receptors undergo enhanced degradation
following the application of TSP1 (Kaur et al., 2011). In this
case, TSP1/CD47 interaction acts as a destabilizing factor
that reduces receptor degradation with a mechanism not yet
understood.
ERK1/2 activation and calcium elevation are important
downstream endpoints in VEGF-mediated angiogenic response
(Meadows et al., 2001; Faehling et al., 2002; Dellinger and
Brekken, 2011; Li et al., 2011; Koch and Claesson-Welsh, 2012).
To investigate the consequences of TSP1 binding to CD47 on
VEGF-mediated angiogenesis, we concentrate on the effects
on ERK1/2 and calcium downstream of VEGFR2. Given the
lack of empirical data and the complexity of the signaling
processes, we set out here to interrogate potential mechanisms
for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and
calcium by TSP1/CD4 interaction utilizing a detailed rule-based
model of VEGF signaling to ERK1/2 and calcium incorporating
VEGFR2, the co-receptor NRP1, and the detailed dynamics of
the receptors. We then included CD47 and TSP1 in this model
and carried out exploratory in silico simulations to formulate
biological mechanisms that would explain and synthesize the
available qualitative data. Specifically, we focused on the effects
of TSP1 on VEGFR2 receptor dynamics and stability, as well as
the empirically suggested inhibition of agonist induced calcium
elevation mediated by the inhibition of calcium release-activated
calcium channels (CRAC) by TSP1 (Bauer et al., 2010). The
model was then applied to quantitatively assess pro-angiogenic
therapeutic interventions involving TSP1 and CD47 inhibition
with possible utility in pathological conditions such as PAD.
MATERIALS AND METHODS
The biological rules for receptor interactions and signal
transduction to downstream signaling are incorporated in
BioNetGen, with the text file (with.bngl extension) given in the
Supplementary Material Section. We also included the SBML file
associated with the model.
Table S1 contains the list of parameters and their description.
Table S2 contains the initial values for the seed species in the
model. The rules generate 627 species and 4174 reactions.
Binding of PLCγ to pVEGFR2 and subsequent
phosphorylation and dissociation of PLCγ from the receptor is
described by a Michaelis-Menten type reaction as follows:
pVEGFR2+ PLCγ → pVEGFR2+ pPLCγ
Rate=
kpPLCγ [pVEGR2][PLCγ ]
KmPLCγ /R2 + [PLCγ ]
(1)
pVEGFR2 denotes all the species containing phosphorylated
VEGFR2 which is determined by BioNetGen. Using this
approach lowers the number of reactions generated by the rules
and prevents combinatorial explosion in the model.
Ras activation by S1P is modeled as a Michaelis-Menten type
reaction as follows:
RasGDP + S1P→ RasGTP + S1P
Rate =
kS1P/Ras[S1P]
[S1P]+ KmS1P/Ras
(2)
with parameters kS1PRas and Km,S1PRas determining the strength
of Ras activation by S1P.
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Current through the CRAC channels is modeled according
to the following equation. This model is a simplified version of
the CRAC component of the mathematical model developed by
Schmeitz et al. (2013) in T-cells:
dJCRAC
dt
=
ICRAC − JCRAC
τCRAC
ICRAC =
I¯CRACK
4.2
CRAC
K4.2CRAC + Ca
4.2
ER
(3)
The steady-state current (Equation 4) as a function of ER calcium
concentration is described by an empirically determined Hill
function (Luik et al., 2008).
The output from BioNetGen was saved into C programming
language file with MEX functionality which is readable from
within MATLAB (the Mathworks Inc., Natick, MA, 2015). The
set of ordinary differential equations (ODEs) describing the
reaction network was numerically integrated using SUNDIAL
numerical solver suite (Hindmarsh et al., 2005). The direct search
method implemented in the patternsearch function in MATLAB
was utilized for parameter fitting.
Western blot images were extracted and analyzed using the
software imageJ (Schneider et al., 2012).
Global sensitivity analysis was performed using the partial
rank correlation coefficient (PRCC) algorithm described in
Marino et al. (2008). The parameter values for sensitivity analysis
were randomly chosen from a uniform distribution within a
range 0.01× fitted value ≤ p ≤ 50× fitted value.
RESULTS
Rule-Based Computational Model of VEGF
Signaling to ERK1/2 Incorporating
TSP1/CD47 Interaction
To accurately capture receptor dynamics and signaling to
downstream targets, we opted to use a rule-based modeling
approach where molecular details of the species and the
corresponding rules for the interactions are implemented
in a programing environment such as BioNetGen (see the
supplementary material for the BioNetGen file) (Faeder et al.,
2009; Hlavacek and Faeder, 2009). The program utilizes
biological rules to automatically generate the interaction
network outputting all the relevant species and chemical
reactions. This approach takes into account the combinatorial
complexity inherent in multi-domain protein interactions.
Another advantage is that the program has a modular structure
with parameters, seed species, and reaction rules provided in a
single file for easy access and analysis. Figure 1A shows the seed
species that are used as input to themodel with the corresponding
binding andmodification sites. VEGF has three binding sites, two
for binding to receptors, and a third binding site for binding to
NRP1 (Parker et al., 2012). VEGFR2 has three sites: the ligand
binding domain to VEGF (L), a ligand-independent coupling
site to VEGFR1 or VEGFR2 (C) (Neagoe et al., 2005), and a
tyrosine site modifiable by phosphorylation/de-phosphorylation
(denoted by Y1175, but it should be interpreted as the lumping
of all the relevant phosphorylation modification sites into a
single site). CD47 has a binding site for TSP1 and another
domain capable of binding and associating with VEGFR2 there
is evidence to suggest that CD47 is also associated with signal
regulatory protein α [SIRPα and that this interaction maybe
important in TSP1 effects in endothelial cells (Yao et al., 2014).
Here we assume that CD47/SIRPα are lumped together and
modeled as a single agent]. VEGFR1 has a ligand binding site
(L), a ligand-independent coupling site to VEGFR1 and VEGFR2
(C), and a binding domain for NRP1 (NRP1bd). NRP1 has a
single binding site that is capable of binding competitively to
either VEGF or VEGFR1 (R1bd/L) (Fuh et al., 2000). TSP1 has a
single binding site for CD47. Rules for VEGF dependent receptor
dimerization and VEGF binding to NRP1 with subsequent
binding to VEGR2 and dimerization are shown in Figure 1B.
The rule for TSP1 binding to CD47 is illustrated in Figure 1C.
Figure 1D depicts the rules for the interaction between VEGFR1
and NRP1. The rule for VEGF-mediated hetero-dimerization of
VEGFR1 and VEGFR2 is also shown. The rule for the binding
between CD47 and VEGFR2 is also drawn. In the absence of
ligand, VEGFR1 and VEGFR2 can pre-dimerize (Figure 1E). The
rule for VEGFR2 auto-phosphorylation and dephosphorylation
is also shown (Figure 1E). Receptor complexes containing
VEGF/VEGFR2 heterodimers can undergo endocytosis followed
by degradation as illustrated by Figure 1F. CD47 is assumed
to undergo recycling and degradation when associated with
VEGFR2.
The signaling pathway from phosphorylated VEGFR2 to
ERK1/2 and calcium is depicted in Figure 1G. The pathway
was constructed by reviewing the literature evidence for the
components of VEGF mediated ERK1/2 activation and the
relevant pathway information contained in Reactome database
(Milacic et al., 2012; Croft et al., 2014). ERK1/2 activation
downstream of VEGFR2 is dependent on PKC and the positive
feedback resulting from the phosphorylation of SphK1 by
pERK1/2, and the subsequent translocation of phosphorylated
SphK1 to the plasma membrane by calcium and integrin binding
protein 1 (CIB1) (Kolch et al., 1993; Shu et al., 2002; Pitson
et al., 2003; Jarman et al., 2010). CIB1 contains a myristoyl switch
that is activated by the binding of calcium. Once in the plasma
membrane, SphK1 phosphorylates and generates S1P which then
activates Ras. While the exact mechanism for the activation of
Ras by S1P is not known, it is thought to involve the inhibition of
a GTPase activating protein.
One distinguishing feature of the model here is the
incorporation of a detailed calcium module downstream of
VEGFR2 that includes release from the endoplasmic reticulum
(ER) via the IP3 sensitive receptors and calcium regulation
involving plasmamembrane and SERCA pumps. CRAC channels
are also a prominent hallmark of the calcium cycling module
(Figure 1H) (see methods for the description of the CRAC
channel model). The model for calcium dynamics including
calcium buffering in cytoplasm and the ER is similar to the
model developed in Silva et al. (2007). The computational
model is parameterized by fitting the model simulations to
a consistent set of published experimental data on VEGFR2
receptor dynamics, dynamics of various phosphorylated species
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FIGURE 1 | Rules and pathways for VEGF signaling to calcium and ERK1/2. (A) Seed species used as input into BioNetGen including VEGF, VEGFR1,
VEGFR2/CD47, NRP1, and TSP1. (B) Schematic representation of the rules for VEGF-mediated receptor dimerization, VEGF interaction with NRP1, (C). TSP1
binding to CD47 on the cell surface, (D). Ligand-independent VEGFR1 binding to NRP1 and multi-complex formation, VEGF-mediated heterodimer formation
between VEGFR1 and VEGFR2. Binding of CD47 to VEGFR2 to form a preassociated complex, (E). Ligand-independent dimer formation resulting in
VEGFR2/VEGFR2, VEGFR1/VEGFR1, and VEGFR1/VEGFR2 heterodimers. The rule for autophosphorylation is also shown, (F). Internalization of the complexes that
contain VEGF/VEGFR2/VEGFR2 homodimers. (G) Signal transduction pathway from the phosphorylated tyrosine to ERK1/2 and calcium incorporating SphK1
feedback and translocation utilizing CIB1, (H). Calcium cycling module incorporating IP3-dependent release from the ER, CRAC, and calcium regulation with plasma
membrane and SERCA pumps.
and the dose-response curves for the activation of VEGFR2
and ERK1/2. The model is simultaneously fitted to the available
data to estimate and constrain the parameters. Global sensitivity
analysis is also performed to isolate the most significant
parameters affecting model dynamics. The list of the parameter
values along with their description is included in Table S1 as
part of the Supplementary Material. Receptor levels are shown
in fraction total for ease of comparison with the experimental
measurements.
Model Simulations and Sensitivity Analysis
In Figure 2A, the total VEGFR2 level from the model (solid blue)
is fitted to the two sets of experimental data (red and black circles)
(Bruns et al., 2010; Ballmer-Hofer et al., 2011). After 180 min
of continuous exposure to VEGF, over 80% of the receptors are
degraded. Empirical data suggest that NRP1 stabilizes VEGFR2
at the cell surface and that in the absence of NRP1, VEGFR2
recycling to the plasma membrane is seriously hindered. As
shown in Figure 2B, the model is constrained by simulating the
effect of the absence of NRP1 by fitting the simulated VEGFR2
level from the model to the data (red circles) (Ballmer-Hofer
et al., 2011). The control curve (black) shows that after 180
min of VEGF exposure, the cell retains 20% of the receptors. In
the absence of NRP1, however, all the receptors are degraded
(blue). The fitted values of the parameters for internalization,
membrane recycling, and degradation reveal that in the absence
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FIGURE 2 | Model parameterization. (A) Total VEGFR2 (R2) computed as fraction total versus time fitted to two sets of experimental data from Bruns et al. (2010)
and Ballmer-Hofer et al. (2011) (red and black circles), (B). R2 versus time with (blue) and without (black) NRP1 fitted to the data in Ballmer-Hofer et al. (2011) (red
circles), (C). Surface level of VEGFR2 constrained with two sets of experimental data from Ewan et al. (2006) and Bruns et al. (2010) (red and black circles). (D)
Fraction of phosphorylated receptors (pR2) is fitted to the experimental data in Chabot et al. (2009) (red circles). (E) Phosphorylated PLCγ from the model fitted to the
data in Chabot et al. (2009) (red circles). (F) Normalized calcium transient from the model fitted to the normalized experimental data in Li et al. (2011) (red circles). (G)
Raw calcium trace corresponding to the normalized transient in (F). (H) pERK1/2 fit to the data in Chabot et al. (2009) (red circles). (I) SphK1 inhibition abolishes
pERK1/1 consistent with the data in Shu et al. (2002) (red versus blue curves). (J) Binding of VEGF to the binding sites on the cell surface versus VEGF concentration
(Bikfalvi et al., 1991), (K). Dose response curve for pR2 is fitted to the experimental data in Whitaker et al. (2001) (red circles), (L). Dose response curve for the
activation of ERK1/2 is fitted to two sets of data from Wijelath et al. (2006) and Yu et al. (2015) (red and black circles). The inset indicates sudden jump in pERK1/2 as
VEGF in increased above threshold.
of NRP1, the recycling rate to the membrane from the endosomal
compartment is substantially decreased (0.756 s−1 vs. 1.24 ×
10−3 s−1). This reduction in recycling rate is sufficient to explain
the rapid decay of total cellular receptor levels in the absence
of NRP1. In fact, it is the combined effects of internalization,
recycling, and degradation that determine the rapid decay of
VEGFR2 cellular level (Figure 2B). The surface fraction of
VEGFR2 is fitted to two sets of experimental data gathered by
flow cytometry (red circles) (Ewan et al., 2006) or Western blot
(red circles) (Figure 2C) (Bruns et al., 2010). Surface receptors
undergo rapid internalization upon continuous VEGF exposure.
The model demonstrates rapid VEGFR2 internalization within
the first 5 min (60% internalized in ∼5 min). The fraction
of phosphorylated VEGFR2 (pR2) and phosphorylated PLCγ
are fitted to the experimental data (Chabot et al., 2009) (red
circles) as shown in Figures 2D,E. To determine the values
of the relevant parameters governing calcium dynamics, the
normalized calcium concentration in the cytoplasm (Figure 2F,
blue) is fitted to the normalized experimental data (Figure 2F,
red circles) (Li et al., 2011). The raw trace is shown in Figure 2G
indicating a transient amplitude of ∼250 nM consistent with
experimental measurements (Faehling et al., 2002). Figure 2H
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shows the ERK1/2 activation signal fitted to the data from
human umbilical vein endothelial cells (HUVEC) (Chabot et al.,
2009). The model is constrained by the experimental evidence
that blocking SphK1 inhibits ERK1/2 activation (Figure 2I) (Shu
et al., 2002). The parameters for VEGF binding to the receptors
on the cell surface are constrained by the experimental data
for VEGF binding to the available binding sites on the cell
(Bikfalvi et al., 1991) (Figure 2J). The dose-response data for
phosphorylated receptors are also utilized (Figure 2K) (Whitaker
et al., 2001). To constrain the dose-response of ERK1/2, we
utilized two sets of data in HUVEC (Wijelath et al., 2006) (black
circles) and pulmonary arterial endothelial cells (PAEC) (Yu
et al., 2015) (red circles). Constraining the model revealed a
surprising switch-like behavior in ERK1/2 activation occurring
at ∼5 pM VEGF, implying the existence of threshold in VEGF
activation of ERK1/2 at 5 pM. The plot in the inset illustrates
this sudden jump in pERK1/2 signal at 5 pM VEGF. Another
interesting emergent feature of the model is the prediction that
the activation of VEGFR2 at the surface is transient, decaying
to the baseline in less than 10 min, while the main signaling
occurs from the internalized receptors, sustained for 30 min
(Figures S1A,B). This is consistent with current experimental and
computational modeling evidence arguing for the critical role of
endocytosis in shaping and regulating VEGFR2 signaling (Zhang
et al., 2013; Clegg and Mac Gabhann, 2015). Figures S1C–F also
shows the predicted traces for the activation of PKC, Ras, Raf,
and the dose-response curve for RasGTP, with the same threshold
behavior as ERK1/2.
To identify sensitive parameters involved in VEGFR2
activation, we carried out global sensitivity analysis summarized
in Figures S1G,H. Not surprisingly, the total VEGFR2 level is
the most sensitive parameter affecting pVEGFR2 with positive
correlation. The next in the ranking are parameters describing
the interaction between VEGFR2 and NRP1. The top ranking
negatively correlated parameter is the degradation rate of
VEGFR2. The next on the list are parameters determining the
interaction of VEGFR2 and NRP1 (see Table S1 for the detailed
description of the parameters along with their values). Figure S2
summarizes the result of global sensitivity analysis identifying
positive and negatively correlated parameters affecting ERK1/2
activation.
As discussed previously, there is empirical evidence for the
enhanced degradation of VEGFR2 following TSP1 application
(Kaur et al., 2011). In the next section, we utilize the model
to perform predictive simulations to test whether the enhanced
degradation of VEGFR2 is sufficient to explain the TSP1
inhibitory effects on VEGF signaling to ERK1/2 and calcium.
Can Enhanced VEGFR2 Degradation
Initiated by TSP1 Binding to CD47 Explain
the Inhibitory Effects of TSP1?
We simulate the direct effect of TSP1 by assuming that CD47
binding to TSP1 leads to accelerated VEGFR2 degradation. It
is assumed that TSP1/CD47/VEGFR2 undergo internalization
together and either recycle back to the membrane or degrade
with a higher degradation rate (shown schematically in Figure
1F). In cells devoid of C47, VEGFR2 signaling is not affected by
TSP1. This implies that TSP1/CD47 interaction is necessary for
VEGFR2 degradation. For the simulations here, cells are exposed
to 2 nM TSP1 for 10 min, followed by 40 min exposure to 50
ng/ml VEGF. This is similar to the experimental protocol in Kaur
et al. (2010). According to Figure 3A, maximum fractional pR2
and pR2 at 10 min decline rapidly as the degradation rate of
VEGFR2 is increased. Indeed, a 5-fold increase in degradation
rate is sufficient to essentially abolish the plateau phase of
the pR2 signal (Figure 3A, red). Figure 3B demonstrates this
more clearly by showing pR2 traces for different values of the
degradation rate (indicated in the legend as fold changes). A 5-
fold increase in the degradation rate is predicted to be sufficient
to significantly decrease the activation of VEGFR2 (blue versus
black traces). Figures 3C,D demonstrates that the enhanced
degradation mechanism is very effective in inhibiting the calcium
transient generated downstream of VEGFR2. ERK1/2 activation
is robust until a critical value of the degradation rate is reached
as shown in Figure 3E (∼21-fold increase relative to the base
value, or 0.03 s−1). Samples traces for four different degradation
rates are also shown in Figure 3F. Figure 3G investigates the
effect of enhanced degradation of VEGFR2 and external TSP1
concentration on maximum pERK1/2 signal. Accordingly, if
VEGFR2 degradation is accelerated by 50-fold, at least 0.52 nM
TSP1 concentration is required for the inhibition of ERK1/2
signal. This is consistent with empirical data suggesting that TSP1
inhibits VEGFR2 signaling at concentrations above 0.6 nM (Kaur
et al., 2010). Figure 3G further predicts that∼33-fold increase in
VEGFR2 degradation is required for the inhibition of VEGFR2
signaling by 0.6 nM TSP1.
The effect of VEGFR degradation and CD47 surface levels
on ERK1/2 activation is investigated in Figure 3H. TSP1
concentration is 2 nM for these simulations. The decline in the
effect of TSP1 is very steep as CD47 levels are reduced from
5 receptors/µm2 (7000 receptors per cell) to 2.2 receptors/µm2
(3100 receptors per cell). Figure 3H further predicts that
increasing CD47 levels beyond 5 receptors/µm2 does not affect
TSP1 inhibition of VEGFR2 signaling.
Overall, the results here demonstrate that the enhanced
degradation of VEGFR2 by TSP1/CD47 interaction is a viable
mechanism to explain the global shutdown of VEGFR2 signaling.
The dependence on TSP1 concentration is also consistent with
the experimental data indicating the viability of the enhanced
degradation mechanism.
Phosphatase Recruitment to VEGFR2 by
TSP1/CD47 Interaction May Augment the
Inhibitory Effects of TSP1 on VEGF
Signaling
We next consider the hypothesis that TSP1 might insert some
of its inhibitory effects on VEGFR2 by recruiting phosphatases
to the receptor complex. For the simulations here the cells
are exposed to 2 nM TSP1 for 10 min, followed by the
addition of VEGF for 40 min. It is assumed that the increase
in dephosphorylation rate is the sole mechanism. As shown
in Figure 4A, maximum fractional pR2 and pR2 at 10 min
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FIGURE 3 | TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. Two nanometer TSP1 is added for 10 min followed by 40 min of 50
ng/ml VEGF. (A–F) pR2 (A,B), calcium (C,D), and pERK1/2 (E,F) response as VEGFR2 degradation is increased. ERK1/2 exhibits threshold behavior in response to
receptor degradation rate (E). (G) Maximum pERK1/2 as a function of TSP1 concentration and the fold-change in VEGFR2 degradation in the presence of TSP1. The
dark blue region is the parameter regime where no ERK1/2 activation is observed, (H). Maximum ERK1/2 as a function of CD47 level [# (number) per surface area]
and the fold-change in VEGFR2 degradation with TSP1 present.
decline rapidly as the dephosphorylation rate (induced by
TSP1/CD47 binding) increases. Sample traces are shown in
Figure 4B. As shown by the figure, ∼80-fold increase in
VEGFR2 dephosphorylation rate is sufficient to essentially
collapse the pR2 signal (blue versus black trace). Enhanced
dephosphorylation is also very effective in shutting down
calcium elevation downstream of VEGFR2 as demonstrated by
Figures 4C,D. To block ERK1/2 activation the model predicts at
least ∼90 fold increase in dephosphorylation rate at 2 nM TSP1
(Figure 4E). Sample pERK1/2 traces are shown in Figure 4F.
Increasing dephosphorylation delays ERK1/2 activation until
the threshold dephosphorylation value is reached beyond which
there is no pERK1/2 signal (flat purple trace). Figures 4G,H
summarize the effects of combined enhanced degradation and
phosphatase recruitment on maximum pERK1/2 at two different
TSP1 concentrations shown experimentally to inhibit VEGFR2.
The surface plots demonstrate that the two mechanism can
work in tandem to inhibit VEGFR2 signaling to ERK1/2. For
example, 10-fold increase in VEGFR2 degradation and 51-fold
increase in VEGFR2 dephosphorylation rate is predicted to be
sufficient to inhibit ERK1/2 activation at 0.6 and 2 nM TSP1.
Interestingly, consistent with experimental data, 0.2 nM TSP1
is not effective at inhibiting VEGFR2 signaling within a wide
range of degradation and dephosphorylation rates (Figure 4I).
Further, 50% reduction in cellular CD47 makes cells resistant
to TSP1 effects (Figure 4J). In all, these simulations synthesize
the available experimental data on the inhibitory effect of
TSP1 on VEGF signaling and demonstrate quantitatively that
enhanced degradation of VEGFR2 coupled with phosphatase
recruitment to the receptor by TSP1 are effective mechanisms
in shutting down VEGF signaling at physiological concentrations
of TSP1.
Next, we consider a different layer of TSP1 effects involving
the experimentally suggested alteration of calcium signaling by
TSP1 (Bauer et al., 2010) and the consequent effect on ERK1/2
dynamics.
TSP1 Inhibition of CRAC Channels Affects
Calcium Elevation and ERK1/2 Dynamics
Recent experimental evidence suggests that TSP1 inhibits the
ionomycin-induced calcium elevation (Bauer et al., 2010). This
inhibitory effect may be attributed to the inhibition of CRAC
channels by TSP1 with a mechanism not yet understood. The
consequences of inhibiting CRAC current amplitude and the
activation time constant are studied in Figure 5. As shown in
Figure 5A, the calcium transient amplitude does not change
appreciably as the current amplitude is inhibited from its
base value of 1.74 × 104 µM/s. Sample calcium transients
are shown in Figure 5B predicting profound effects on the
duration and plateau phase of the calcium transients. The
inhibition of CRAC current is also not predicted to affect
the maximum of ERK1/2 activation signal (Figure 5C), but
significantly influences the plateau phase and duration of
pERK1/2 (Figure 5D). Interestingly, the change in activation
time constant of the current through the CRAC channels does
not affect ERK1/2 activation as illustrated by Figures 5E,F.
The simulations demonstrate that within the context of the
model here, the hypothesized TSP1 inhibition of CRAC current
amplitude, but not current activation dynamics, is capable of
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FIGURE 4 | Enhanced dephosphorylation of VEGFR2 via TSP1-mediated phosphatase recruitment. (A,B) Max pR2 and pR2 at 10 min vs. the fold-change in
VEGFR2 dephosphorylation rate for receptors containing TSP1 with sample traces, (C,D) Max [Ca] as a function of the fold decrease in the rate of receptor
dephosphorylation and sample traces, (E,F) Maximum pERK1/2 vs. fold-change in dephosphorylation rate and sample traces showing the threshold behavior, (G–I)
Max pERK1/2 as a function of enhanced VEGFR2 degradation (shown as fold-change relative to control with no TSP1) and the fold-change in receptor
dephosphorylation rate for 2, 0.6, and 0.2 nM TSP. This identifys the parameter regime for effective ERK1/2 inhibition (dark blue regions). there is no inhibition with
[TSP1] = 0.2 nM (I). (J) Max pERK1/2 as a function degradation and dephosphoryation rates with 50% reduction in CD47 levels and 2 nM TSP1.
profoundly impacting calcium transient and ERK1/2 activation
signal morphology.
Targeting TSP1 and CD47 As Potential
Strategies in Restoring VEGFR2 Signaling
Considering the function of TSP1 as a potent inhibitor
of VEGF signaling to calcium and ERK1/2 activation, here
we carry out proof-of-principle simulations to demonstrate
the effectiveness of TSP1/CD47 inhibition as a strategy for
restoring VEGF signaling. The effect of TSP1 inhibition (such
as the application of anti-TSP1 antibody, inhibition of TSP1
secretion, or siRNA against TSP1 transcript) is modeled in a
simple manner by lowering the concentration of TSP1 and
monitoring the recovery of calcium and pERK1/2 signals. We
consider a mixed mechanism involving enhanced VEGFR2
degradation (10-fold) and increased VEGFR2 dephosphorylation
(51-fold). These values are consistent with the two-parameter
scan in Figures 4G,H. The inhibition of CD47 is modeled
by depleting CD47 (e.g., by anti-CD47 antibody or the
use of morpholinos) and monitoring calcium and pERK1/2
signals. It is further assumed that 2 nM TSP1 and 50 ng/ml
VEGF are simultaneously added. TSP1 is capable of inhibiting
VEGF signaling when added simultaneously with VEGF as
demonstrated by Figures S3A–D for enhanced degradation
mechanism and Figures 6E–H for increased dephosphorylation).
As demonstrated in Figures 6A–D for TSP1 inhibition, both
calcium and pERK1/2 signals are eventually restored by
sufficiently high TSP1 inhibition. Note that calcium signal is
unresponsive to TSP1 inhibition until at least 80% inhibition
is achieved. Sample calcium transients are shown in Figure 6B,
clearly demonstrating calcium recovery in response to TSP1
inhibition. Similarly, as shown in Figure 6C, inhibiting TSP1
restores ERK1/2 activation and that threshold for ERK1/2
signal recovery is ∼72% inhibition. Sample pERK1/2 traces
are also included in Figure 6D showing the recovery of the
ERK1/2 signal as TSP1 is inhibited. The high TSP1 inhibition
threshold (80% for calcium and 72% for ERK) implies that
TSP1 inhibition might be challenging as a therapeutic strategy
as it would require sustained and high TSP1 inhibition,
highlighting the need for effective drug delivery technology
capable of achieving above-threshold TSP1 inhibition in
vivo.
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FIGURE 5 | CRAC channel inhibition and VEGF signaling to ERK1/2 and calcium. (A) Max Ca versus CRAC channel amplitude, (B). Ca2+ traces for different
CRAC channel current values. (C) Max pERK1/2 vs. current showing no appreciable effect. (D) pERK1/2 traces showing prolongation of pERK1/2 signal in response
to increase in the current. (E) Max pERK1/2 and pERK (at 10 min) as a function of the time constant for the activation of the CRAC current. (F) pERK1/2 traces for five
different values of the time constant.
FIGURE 6 | TSP1 and CD47 inhibition and the restoration of VEGF signaling. (A–D) TSP1 inhibition and the recovery of the calcium (A,B) and pERK1/2 signal
indicating 72% inhibition threshold for effective recovery (C,D). TSP1 inhibition involves 10-fold increase in VEGFR2 degradation and 51-fold increase in
dephosphorylation relative to the case with no TSP1. (E–H) VEGF signal recovery by CD47 depletion. (E,F) intracellular calcium recovery as CD47 is depleted along
with sample traces, (G,H) ERK1/2 activation is restored when 18% of CD47 is depleted. Sample traces are also shown.
The effect of depleting CD47 as a therapeutic strategy
is summarized in Figures 6E–H. Note the stark contrast
between calcium recovery curves in Figures 6E,A. According to
Figure 6E, calcium signal responds readily to CD47 depletion
and the recovery is rapid after 50%CD47 depletion. Sample traces
are shown in Figure 6F clearly showing that calcium signaling is
restored by CD47 inhibition and that CD47 inhibition is more
effective that TSP1 inhibition in restoring the calcium transient.
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ERK1/2 activation is restored following depletion of only 18%
of CD47, once again much more effective than TSP1 inhibition
(Figure 6G vs. Figure 6C). Sample pERK1/2 traces are shown in
Figure 6H demonstrating the recovery of the ERK1/2 activation
signal.
The simulations demonstrate that CD47 depletion may be a
more effective strategy than targeting TSP1 in restoring VEGF
signaling to calcium and ERK1/2. CD47 depletion is particularly
effective in restoring ERK1/2 activation downstream of VEGFR2.
DISCUSSION
Inhibition of VEGF signaling is a hallmark of anti-angiogenic
function of TSP1. Given the scarcity of experimental data
elucidating the precise inhibitory mechanisms, we attempted at
undertaking an in silico approach to computationally investigate
potential mechanisms of inhibition. The model incorporated
detailed molecular mechanisms using a rule-based model for
receptor-receptor interaction and a coarse-grained model for
signaling to calcium and ERK1/2 from the activated receptors.
The inclusion of detailed calcium cycling module in the model
allowed us to study the role of TSP1 in inhibiting calcium
signaling and the potential crosstalk with ERK1/2 activation.
Fluorescene resonance energy transfer based (FRET-based)
experiments in endothelial cells had shown the preassociation
of VEGFR2 with CD47 in endothelial and T cells (Kaur et al.,
2010, 2014). We hypothesized that TSP1 binding to CD47
might enhance VEGFR2 degradation. Our simulations predicted
that this enhanced-degradation scenario is indeed capable of
explaining TSP1 effects on VEGFR2 phosphorylation, calcium
elevation, and ERK1/2 activation. This TSP1/CD47 dependent
enhanced degradation was consistent with the experimental data
indicating that the knock-down of CD47 protected against TSP1
inhibition of VEGFR2 (Kaur et al., 2010).
An interesting prediction of the model was that the effect
on ERK1/2 activation is switch-like, implying that ERK1/2
activation is robust until a threshold value of the degradation
rate is reached. This result is consistent with recent data in
cancer cells demonstrating that repression of TSP1 expression
is a critical step in establishing the angiogenic switch in
tumor cells, the transformation from avascular to vascularized
tumors (Watnick et al., 2015). Our simulations corroborate the
existence of a switch-like mechanism in TSP1 inhibition of
VEGFR2 signaling. Moreover, simulations show that VEGFR2
phosphorylation was more sensitive to TSP1-induced enhanced
receptor degradation than ERK1/2 activation. ERK1/2 activation
was robust until the degradation rate was increased by over
21-fold (see Figures 3E,F), while VEGFR2 phosphorylation was
drastically inhibited by only a 5-fold increase in the degradation
rate (Figures 3A,B). This predicted differential sensitivity of the
model to TSP1 suggests that simultaneous assaying for ERK1/2
activation and VEGFR2 phosphorylation maybe important in
experimental studies aiming to investigate the mechanism of
TSP1 action on VEGF signaling. By itself, VEGFR2 response to
TSP1 is not a straightforward linear predictor of downstream
ERK1/2 effects.
Another mechanism considered here was the increase in
VEGFR2 dephosphorylation by TSP1-induced recruitment
of phosphatases to VEGFR2/CD47 complex. Simulations
demonstrated that the two inhibitory mechanisms may work
together to effectively inhibit VEGF signaling.
Simulations here also proposed the possibility of inhibiting
TSP1 or CD47 as potential interventions for restoring VEGF-
mediated angiogenic response. The model showed that
sequestering TSP1 effectively normalized calcium signaling
and ERK1/2 activation, albeit requiring at least 80% inhibition.
This high threshold for inhibition might preclude the in vivo
applicability of this strategy in restoring angiogenesis in diseases
such as PAD. In related simulations, the computer model
predicted that CD47 depletion is more efficient at restoring
calcium and ERK1/2 activation (with lower hysteresis). Indeed,
only 18% depletion of CD47 was needed to restore ERK1/2
activation signal compared with 72% TSP1 inhibition. The
results highlight the important role of efficient and sustained
therapeutic agent delivery to affected tissues to ensure above-
threshold inhibition of TSP1 and CD47. They further suggest
that CD47 depletion should be considered as an initial approach
in pro-angiogenic therapeutic intervention. It is plausible that
different endothelial cell types may exhibit differential inhibition
thresholds to TSP1 and CD47 which would further necessitate
the need for sustained delivery of anti-TSP1 and anti-CD47
agents.
Further complicating anti-TSP1 therapy, platelets contain
significant pre-formed TSP1 that are a depot source of protein.
Thus, targeting CD47 is an alternative strategy expected
to be more efficient at preserving pro-angiogenic signals.
Additionally, VEGF can also signal via NO while CD47
can interact with cell membrane SIRPα (Yao et al., 2014).
Analysis of TSP1-VEGF signaling in relation to these additional
components will be important in future extensions of the current
model.
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